Journal article

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials

Jeffrey Jones, Anthony Mato, Steven Coutre, John C Byrd, Richard R Furman, Peter Hillmen, Anders Osterborg, Constantine Tam, Stephan Stilgenbauer, William G Wierda, Nyla A Heerema, Karl Eckert, Fong Clow, Cathy Zhou, Alvina D Chu, Danelle F James, Susan M O'Brien

British Journal of Haematology | WILEY | Published : 2018


Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1-12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow-up of 28 months, overall response rate was 85% and estimated 30-month progression-free and overall survival rates were ..

View full abstract